Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000378:metabolism*; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D002469:Cell Separation; D002478:Cells, Cultured; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005838:Genotype; D006801:Humans; D007694:Killer Cells, Natural / Q000166:cytology* / Q000187:drug effects* / Q000276:immunology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D020559:Monomeric GTP-Binding Proteins / Q000235:genetics / Q000378:metabolism; D011719:Pyrazines / Q000494:pharmacology*; D053218:Receptors, Death Domain / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects
D018952:Antigens, CD34; D001897:Boronic Acids; D011719:Pyrazines; D053218:Receptors, Death Domain; D000069286:Bortezomib; C490245:GEM protein, human; D020559:Monomeric GTP-Binding Proteins